ArticleClinical & experimental metastasis2005
A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: implication in tumor metastasis.
Article in Clinical & experimental metastasis, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics.medRxiv : the preprint server for health sciences · 2023Article
- CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.Frontiers in oncology · 2022Review
- Identification of a 3-gene signature for predicting the prognosis of stage II colon cancer based on microsatellite status.Journal of gastrointestinal oncology · 2021Article
- Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome ofCancer biology & medicine · 2019Article
- Matrix metalloproteinases in the brain and blood-brain barrier: Versatile breakers and makers.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2016Review
- Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.PloS one · 2015Article
- MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.The Prostate · 2014Review
- A hybrid model of tumor-stromal interactions in breast cancer.Bulletin of mathematical biology · 2013Article
- Targeting bone physiology for the treatment of metastatic prostate cancer.Clinical advances in hematology & oncology : H&O · 2013Review
- Regulation of cell proliferation and migration in glioblastoma: new therapeutic approach.Frontiers in oncology · 2013Article
- Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma.TheScientificWorldJournal · 2013Review
- Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.Human mutation · 2013Article
- miR451 and AMPK mutual antagonism in glioma cell migration and proliferation: a mathematical model.PloS one · 2011Article
- Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Purification and preliminary X-ray crystallographic studies of beta-microseminoprotein from human seminal plasma.Acta crystallographica. Section F, Structural biology and crystallization communications · 2009Article
- Regulation of cell invasion and signalling pathways in the pituitary adenoma cell line, HP-75, by reversion-inducing cysteine-rich protein with kazal motifs (RECK).Journal of neuro-oncology · 2008Article
- Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress.Journal of neuroscience research · 2008Article
- Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Article
- The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.Oncogene · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePCK3145 is a synthetic peptide corresponding to amino acids 31-45 of prostate secretory protein 94, which can reduce experimental skeletal metastases and prostate tumor growth in vivo. Part of its biological action involves the reduction of circulating plasma matrix metalloproteinase (MMP)-9, a crucial mediator in extracellular matrix (ECM) degradation during tumor metastasis and cancer cell invasion. The antimetastatic mechanism of action of PCK3145 is however, not understood. EXPERIMENTAL
designHT-1080 fibrosarcoma cells were treated with PCK3145, and cell lysates used for immunoblot analysis of small GTPase RhoA and membrane type (MT)1-MMP protein expression. Conditioned media was used to monitor soluble MMP-9 gelatinolytic activity by zymography and protein expression by immunoblotting. RT-PCR was used to assess RhoA, MT1-MMP, MMP-9, RECK, and CD44 gene expression. Flow cytometry was used to monitor cell surface expression of CD44 and of membrane-bound MMP-9. Cell adhesion was performed on different purified ECM proteins, while cell migration was specifically performed on hyaluronic acid (HA).
resultsWe found that PCK3145 inhibited HT-1080 cell adhesion onto HA, laminin-1, and type-I collagen suggesting the common implication of the cell surface receptor CD44. In fact, PCK3145 triggered the shedding of CD44 from the cell surface into the conditioned media. PCK3145 also inhibited MMP-9 secretion and binding to the cell surface. This effect was correlated to increased RhoA and MT1-MMP gene and protein expression.
conclusionsOur data suggest that PCK3145 may antagonize tumor cell metastatic processes by inhibiting both MMP-9 secretion and its potential binding to its cell surface docking receptor CD44. Such mechanism may involve RhoA signaling and increase in MT1-MMP-mediated CD44 shedding. Together with its beneficial effects in clinical trials, this is the first demonstration of PCK3145 acting as a MMP secretion inhibitor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.